浙江震元(000705) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the period was CNY 863,465,758.68, reflecting a growth of 6.13% year-on-year[6] - Net profit attributable to shareholders was CNY 22,372,147.99, up 10.94% from the same period last year[6] - Basic earnings per share rose to CNY 0.0670, an increase of 10.93% compared to the previous year[7] - Total operating revenue for Q3 2020 reached RMB 863,465,758.68, a 57.8% increase from RMB 546,650,281.15 in the same period last year[34] - Net profit for the period was RMB 23,315,900.43, representing a 48.0% increase compared to RMB 15,763,085.69 in Q3 2019[34] - Net profit attributable to shareholders was RMB 69,810,468.59, representing a 97.5% increase from RMB 35,350,219.72 in the previous year[36] - Comprehensive income attributable to shareholders was RMB 70,498,212.59, an increase from RMB 36,037,963.72 year-on-year[36] Cash Flow - Net cash flow from operating activities surged by 83.01% to CNY 75,586,021.20[6] - The net cash flow from operating activities for the period is RMB 51,272,480.49, compared to a net outflow of RMB 43,929,455.32 in the same period last year, indicating a significant improvement[38] - The company reported a cash inflow from financing activities of RMB 50,000,000.00, with a net cash flow of RMB 27,968,209.43 for the period[38] - The ending cash and cash equivalents balance increased to RMB 318,015,663.47, up from RMB 194,535,718.44 at the end of the same period last year[38] Assets and Liabilities - Total assets increased by 2.80% to CNY 2,661,136,932.66 compared to the end of the previous year[6] - The company's total liabilities decreased by 47.36% in tax payable to ¥32,289,678.35, due to higher tax payments in the previous year[12] - Total liabilities amounted to approximately ¥660.61 million, with total equity at around ¥1.24 billion, resulting in total assets of approximately ¥1.90 billion[29] - Total liabilities were RMB 896,855,037.20, compared to RMB 876,799,787.52 at the beginning of the period, reflecting an increase of about 2.3%[32] Shareholder Information - The total number of shareholders at the end of the reporting period was 29,676[9] - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 24.93% of the shares[9] Income and Expenses - Total operating costs amounted to RMB 2,408,042,643.85, an increase of 63.9% from RMB 1,467,659,212.55 year-on-year[36] - Research and development expenses decreased by 35.76% to ¥16,722,106.85, mainly due to reduced contract payment expenses by Zhenyuan Pharmaceutical[14] - Sales expenses increased to RMB 132,833,578.77 from RMB 12,982,470.50 in Q3 2019, indicating a substantial rise in operational costs[34] Other Financial Metrics - The company reported a decrease in the weighted average return on net assets to 1.29%[7] - Non-recurring gains and losses amounted to CNY 22,520,446.23 for the year-to-date period[7] - The company reported a significant increase in minority shareholders' profit by 84.88% to ¥3,203,779.54, reflecting increased profitability[14] - Other income rose by 271.28% to ¥6,280,087.18, primarily from government subsidies received by Zhenyuan Pharmaceutical[14]